Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1594-1597, 2005; 10.1373/clinchem.2005.054551
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Panteghini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Panteghini, M.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:1594-1597.)
© 2005 American Association for Clinical Chemistry, Inc.

Opinion

Standardization of Cardiac Troponin I Measurements: The Way Forward?

Mauro Panteghini

Cattedra di Biochimica Clinica e Biologia Molecolare Clinica, Dipartimento di Scienze Cliniche "Luigi Sacco", Facoltà di Medicina e Chirurgia - Polo di Vialba, Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy, Fax 39-02-3564018, E-mail mauro.panteghini@unimi.it

The first 300 words of the full text of this article appear below.

The contribution of laboratory medicine to clinical cardiology has grown in importance over the years. Highly sensitive and specific biomarkers for the detection of myocardial damage, such as cardiac troponins, as well as assays for reliable markers of myocardial function, such as cardiac natriuretic peptides, are now available, assigning to the laboratory a pivotal role in the diagnosis and follow-up of patients with cardiac disease (1). This has been evidenced by the incorporation of these markers into new international guidelines (2)(3)(4). Among those, one of the most important documents outlines the recommendations for a new definition of myocardial infarction (MI), published by the joint European Society of Cardiology and American College of Cardiology committee (2). This consensus document has based the MI definition on biochemical grounds, a choice guided by the advent of cardiac troponins, biomarkers that provide higher sensitivity for smaller myocardial injury and virtually total specificity for cardiac damage (5). It is therefore important that these clinically relevant biomarkers, on which critical decisions will rest, are measured with highly reliable and standardized methods to achieve comparability of results, independent of the measurement test reagents and platforms as well as the laboratory where the procedure is carried out (6). Interchangeability of results over time and location would contribute considerably to improvements in healthcare because results of clinical studies undertaken in different locations or at different times could be universally applied. This would allow effective application of evidence-based medicine, as guidelines established by scientific or professional bodies often advocate use of specific decision limits for diagnosis and therapeutic intervention (3).

Because of an international patent, cardiac troponin T assays from only a single diagnostic manufacturer are commercially available, so that comparability of results for . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C.M. Cobbaert, C.W. Weykamp, E.C.H.J. Michielsen, H. Baadenhuijsen, and M.P. van Dieijen-Visser
Time-Dependent Instability of Cardiac Troponins in Human Plasma Spiked with NIST Reference Material 2921
Clin. Chem., December 1, 2008; 54(12): 2078 - 2079.
[Full Text] [PDF]

Home page
 CirculationHome page
NACB Writing Group Members, F. S. Apple, R. L. Jesse, L. K. Newby, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes
Circulation, April 3, 2007; 115(13): e352 - e355.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
NACB WRITING GROUP MEMBERS, F. S. Apple, R. L. Jesse, L. K. Newby, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, et al.
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes
Clin. Chem., April 1, 2007; 53(4): 547 - 551.
[Full Text] [PDF]

Home page
 CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. G. Miller, G. L. Myers, and R. Rej
Why commutability matters.
Clin. Chem., April 1, 2006; 52(4): 553 - 554.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.